Thanks, perspective Varant, call on forward-looking of right. business strategic our today. to a on everyone joining the us All opportunities for a prepared the thanks remarks zanzalintinib busy The We'll provide Merck. maximize in with view with with for the early-stage ruling the cabozantinib, and today and use been success have a collaboration zanza pipeline extremely and cabo building positive oncology few to the multi-franchise weeks last business. the ANDA announcement to
back our R&D-related address technical Chris had quarter and clarity questions vision saw aspirational be you the momentum commercial Amy and and and here with Zanza validation come dominant company, are cost agreements Exelixis kidney and and sharing, Merck a in position hour working the across pleased mid- third inflection head having in indicators full As in business, Zanza and the literally I our and cabo decade P.J. significant obviously will frame that in a and potentially our significant represents updates is as followed and by any Q&A.
I'll the business. metrics for this cabo's strong XXXX remain for the the Exelixis as to compound important and provides opportunity across in with routinely for of all an commercial is well a Zanza. with at on the momentum half Cabo ANDA XXXX. -- an neck outlook that up that press Dana cancers overview point and all issued release we components revenue growth a and performance very successful of rights. near-term today track ago, an to component from strategic financial we start into we long-term bullish on very XXXXs. maintain global while We're sharing of revenue starting building for commercial and into
As the done collaborative been we're in pleased and success, pillar aim to this a opportunities into one regard future. model to and not cabo get expand Zanza. development our of moving in competition has other obviously with collaborate the We're with the first
With and a our XXXX. we development planned are pivotal with goal and on GU therapeutic we market and is cabo focus. to main in per plan, Note potentially starting already opportunity GI as trials, launch both zanza leader. I aspirational the and the more zanza ongoing in horizon, arguably including oncology in pole as scope position Exelixis' a X believe GU surpass as the early has leader as be year that scale oncology the planned to one
So is and Zanza. immediate an both priority building cabo in momentum for the GI space
compounds zanza business. with X indications we novel is GI early-stage important plan in Building, INDs and and be developing, and winners into our opportunistically. full of multi-franchise profile potential advance for will prioritize our pursued early-stage clinical pruning behind several close -- pipeline, critically we Additional efficiently GU to accelerating XXX, development. including outside XL-XXX towards as near-term XL and pipeline XPOX advancement a and
the we and everything I differentiation prerequisite only viable the mandatory business commercial filter trial As essence That's and the towards in success. path in p-value the cabo do we're the we're pivotal and in to R&D. before, said applying of future story clinical where that clear
clinical We'll data present efforts a on abstracts to medical sets of those meetings. expect titles provide exciting lot as granularity and and and amount data at major significant STELLAR-XXX with XXXX data from throughout our a accepted XXX we of zanza have are early more We from mature clinical published.
as R&D another plan In Day addition, XXXX we to in well. host
now litigation expect With activities behind development up. the to business ramp future us, we ANDA largely
oncology late-stage differentiation are we clinical in success. space, where conviction clinical clear targeting that highlighted we have the drive previously, commercial GU assets ultimate As could GI
we've oncology with since indication cabo and the As expansion in been standouts highlighted few terms biotech underwhelming, one revenue previously, launches XXXX being most of have of growth.
thoughtful could unambiguous potentially late-stage on focus asset. any pursue of with we right the for the Echoes doing we selective valuation right transaction very assets. deal a and as opportunity clinical we're the right commercial as So evaluate the type at and pragmatic, of advance
multi-franchise as specifically To to I clear plan the a Finally, to expense with at foreseeable building the running business for committed for end, R&D very and company. we're recent executing we're that be future. an that success levels ambitious want
cash and a the continue is often prioritize and spending commercial to shareholders. intention to success. of and cash late-stage return generate healthy our Our that and rigorously aggressively clinical advance free maximize investments to while towards we portion free to molecules pipeline,
clinical cheaper late into compounds space As never you all know, as success gets advance development.
last previous we we'll So our at did Exelixis course decade. over points to continue as the spending inflection of prioritize the
billion cash $XXX million the over of X underscores pragmatic another to the our the end investing totaling and $X in Our to commitment pipeline years last shareholders. returning flow approach buybacks while in to share balanced
and background midterm our let's with cabo the vision for for key near highlights into that in So details review for drill and the quarter place, and additional Zanza. down
let's as delivered growth First, status year-over-year its Wes X% $XXX new RCC the driven quarter. increased by million Exelixis strength of start of cabo with franchise the revenues grew for the patient quarter net by including maintained leading quarter $XXX outstanding Global third with franchise and franchise, quarter-over-quarter its in bottom cabozantinib performance the financial XXXX revenue. to compared XX% cabozantinib line the and has the XXXX XXXX. third XXXX. in CABOMETYX quarter TKI product year-over-year, top quarter XXXX and starts partners to up third generated and in with compared million, the of net third to XQ U.S. revenues product demand,
the results, total robust guidance we're and P.J. provide have increased our revenue based and year on XXXX. on product will these momentum wind prepared and the into We quarter their up XXXX Chris revenue details net strong for headed commercial full in we year building remarks. and as
our into drive also revenue XXXX The revenue the obviously first growth the subject zanza Exelixis' drive Cabo by near-term upside to which cabo the focusing ANDA starting opportunities our for throughout next We're early future. into through exclusivity. that either XXXXs early of appeal and projected accelerating party. additional and with the as on to potential extends running regulatory significant favorable decade move subject District with XXXX Let's and Court's potential to to revenue ruling, to end as and judgment is pleased the decade. strong
on XXXX, that more net strength of which nearly the $X indication regulatory get net a our of has discounted MSN's of approval projected the remind of U.S. ANDA annually of position by knowledge, not tentative and heavily in indications we Building potential FDA want our clarity leadership highlight in than until to of our conservative filing. growth cancer, X for the billion business, prostate in capturing in the products fourth midterm years and everyone estimates RCC sales quarter therapy off the submission. opportunity new best I cabo's the oral after cabo base is proposed granted share to projections significant in the original for with their potential market traction limited peak with a reach to CRPC,
Let's analysts, We covering attention forward in it cabo and Street's has more to including with largely moving revenue it recently under with a of now our the the positive with Merck. radar and a anticipate gain the zanza. the turn perspective from been ruling over next little Zanza and collaboration half their models. only announced will prominence
a foundation commercial development built cabo's clinical Specifically, success. surpass provides to zanza early is to cabo's framework its plan on expand and and
represents drugs. for and zanza cancer, reinforces standards X one subsequent colon on neck across clinical cadre potential year generic first in head trials of cancer kidney and including cancer current based tumors established with of the regulatory to need annually, pivotal years, zanza a medical plan and large trials approval X as overwhelming these unmet Critically, our success. population as secure first with and Our and lead in progress XXX,XXX approval over indications, then care patients of in early Recent neuroendocrine per and our XXXX cancer,
the ex U.S. through either with level the comments and XXXX, The commercial the additional up of with commercialization a and and could sales first on GU, appropriate line Exelixis indications of trials partner we $X in never evaluation. and with or moving with than projected wave beyond. and zanza Zanza clinical in to new of top early opportunity few label-enabling equally by the other advance the thrilled is split and drive in upside early GI GU advancing built significant new potential second U.S., greater are indications. cabo here GI but depth between pipeline of behind to opportunity the substantial, financial revenue this nearly to We're pipeline, scope trials well.
I'll satisfied a mid-XXs Zanza. this billion into Obviously, as a wave assets and wrap and next
into molecules the either monotherapies in as the and or clinical expectations biopharma. to and molecule pathobiology XXX and to EDC, space partners, compelling multi-franchise lead for goal proprietary a opportunity represent programs all XXX The rapidly biologic development. of checkpoint molecules. Our with tumor ultimate in formats. variety the data best small of goal prioritize generate advancement and lethality or to and full biologics bispecific exceeding modality monoclonal XL inhibitors synthetic is match approaches We're the multiproduct combination with most antibody Exelixis with all the advancing a as oncology with these
release results. an financial XXXX with extensive our So press key quarter of for please hour issued that, ago the milestones quarter. list and achieved see in an corporate our third
over I'll now the to call Chris. turn
